Faculty

Institution

Unit

Venue

Ute Moll

Professor

Stony Brook University

Affiliations

Renaissance School of Medicine

Pathology

Ute Moll is currently serving as a Pathology Professor at Stony Brook University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Ute Moll

Stony Brook University

Professor

You can click a keyword to filter the displayed items

tumor biology molecular biology cancer research genetics cancer biology oncogenes cancer genetics oncology cell biology gene expression cancer genomics molecular cancer cell death medicinal research pharmacology cancer treatment molecular cell biology cancer cells cancer care apoptosis hematology mitochondrial function tumor suppressors gynecologic oncology cell regulation cell cycle cancer immunotherapy genome biology breast cancer membrane biology leukemia enzyme inhibition cellular therapy tumor targeting anti-cancer agents molecular regulation death studies mammalian biology cellular biology genome instability human pathology cancer management cancer risk colorectal cancer hematological malignancies gene regulation medical genetics molecular physiology cancer growth clinical pathology lymphoid neoplasia cytogenetics experimental medicine thanatology viral oncology mutagenesis gene function disease progression host factors human tumors dna damage cell lines tumor formation expression levels clinical mycology human cancer cells oncogenic ras poor prognosis nuclear overexpression cytoplasmic degradation heat shock primary peritoneal carcinoma mutational analysis tumor progression molecular mechanisms nomenclature committee molecular and cellular biology cell research systems biology

Notable Scholarly Works

Notable Federal Grants

Collaborators

CORRECTION: Dynamics of Clonal Hematopoiesis Under Dna-Damaging Treatment in Patients With Ovarian Cancer. Leukemia (2024)

Christopher Maximilian ArendsKlara KoppRaphael HablesreiterNatalia EstradaFriederike ChristenUte Martha MollRobert ZeillingerWolfgang Daniel SchmittJalid SehouliHagen KulbeMaximilian FleischmannIsabelle Ray-CoquardAlain ZeimetFrancesco RaspagliesiClaudio ZamagniIgnace VergoteDomenica LorussoNicole ConcinLars BullingerElena Ioana BraicuFrederik Damm

hematological malignanciescancer geneticsgynecologic oncologytumor heterogeneityovarian cancermedicinecancer carehematologycancer genomicscancer biologyleukemiacancer researchdna-damaging treatmentsurgical oncologyclonal hematopoiesistumor biologyradiation oncologygeneticsoncologymedicinal research

Correction to: Two Hot Spot Mutant P53 Mouse Models Display Differential Gain of Function in Tumorigenesis. Cell Death and Differentiation (2024)

W HanelN MarchenkoS XuS Xiaofeng YuW WengU Moll

cellular senescencecell deathcancer geneticsdifferential gaingeneticsbiologyoncogenescancer cellstumor microenvironmentcancer biologycellular differentiationtumor biologycell biology

Enhancement of Colorectal Cancer Therapy Through Interruption of the Hsf1-Hsp90 Axis by P53 Activation or Cell Cycle Inhibition. bioRxiv (Cold Spring Harbor Laboratory) (2024)

Tamara IsermannKim Lucia SchneiderFlorian WegwitzTiago De OliveiraLena-Christin ConradiValery VolkFriedrich FeuerhakeBjörn PapkeSebastian StintzingBettina MundtFlorian KühnelUte M. MollRamona Schulz-Heddergott

pharmacologycell cycle inhibitiononcologycolorectal cancercolorectal cancer therapy

Gene Expression Markers in Peripheral Blood and Outcome in Patients With Platinum‐Resistant Ovarian Cancer: A Study of the European Gannet53 Consortium. International Journal of Cancer (2024)

Eva ObermayrThomas MohrEva SchusterElena Ioana BraicuEliane TaubeJalid SehouliIgnace VergoteEric Pujade‐LauraineIsabelle Ray‐CoquardPhilipp HarterPauline WimbergerFlorence Joly‐LobbedezSven MahnerUte Martha MollNicole ConcinRobert Zeillinger

platinum-resistant ovarian cancercancer geneticsgynecologic oncologycancer riskovarian cancercancer carehematologycancer genomicsmolecular diagnosticsmedical geneticscancer biologygene expression markershealth sciencescancer researchtumor biologyimmunologygeneticsperipheral bloodoncologyoncogenesmedicinal research

Clonal Hematopoiesis in Whole-Blood and Cell-Free Dna of Ovarian Cancer Patients Undergoing Parp-Inhibitor Treatment: An Exploratory Analysis of the Engot-Ov48/Eudario Trial. Blood (2023)

Christopher Maximilian ArendsKlara KoppNatalia Estrada-BarrerasRaphael HablesreiterNicole ConcinUte MollRobert ZeilingerWolfgang SchmittJalid SehouliHagen KulbeIsabelle Ray-CoquardAlain ZeimetFrancesco RaspagliesiClaudio ZamagniIgnace VergoteDomenica LorussoLars BullingerElena Ioana BraicuFrederik Damm

medicinepharmacologylaboratory medicinehematologycancer researchgynecologic oncologygeneticsconceptual analysisempirical case studiesclonal hematopoiesiscell-free dnaoncologyexploratory analysisparp-inhibitor treatmentovarian cancermolecular medicine

Data From Mitochondrially Targeted P53 Has Tumor Suppressor Activities I in Vivo /I. (2023)

Flaminia TalosOleksi PetrenkoPatricio MenaUte M. Moll

cancer geneticscancer researchmolecular cancermitochondrial functiongeneticstumor suppressorsmolecular biologyoncologyneuro-oncologycancer biologytumor biology

Epichaperome Inhibition Targets Tp53- Mutant Aml and Aml Stem/Progenitor Cells. Blood (2023)

Bing Z. CarterPo Yee MakMuharrem MuftuogluWenjing TaoBaozhen KeJingqi PeiAndrea D. BedoyLauren B. OstermannYuki NishidaSevinj IsgandarovaMary SobieskiNghi NguyenReid T. PowellMargarita Martinez-MoczygembaClifford StephanMahesh BasyalNaveen PemmarajuSteffen BoettcherBenjamin L. EbertElizabeth J. ShpallBarbara WallnerRobert A. MorganGeorgios I. KarrasUte M. MollMichael Andreeff

medicinegene expressioncancer geneticshematologycancer researchgeneticsmolecular biologytumor biology

Supplementary Figure Legends From Mitochondrially Targeted P53 Has Tumor Suppressor Activities I in Vivo /I. (2023)

Flaminia TalosOleksi PetrenkoPatricio MenaUte M. Moll

cancer geneticscancer researchmolecular cancermitochondrial functiongeneticstumor suppressorscancer genomicsmolecular biologyoncologyneuro-oncologymedicinal researchoncogenescancer biologytumor biologycell biology

Supplementary Figures From Recommended Guidelines for Validation, Quality Control, and Reporting of Tp53 Variants in Clinical Practice. (2023)

Bernard LeroyMandy L. BallingerFanny Baran-MarszakGareth L. BondAntony BraithwaiteNicole ConcinLawrence A. DonehowerWafik S. El-DeiryPierre FenauxGianluca GaidanoAnita LangerødEva Hellstrom-LindbergRichard IggoJacqueline Lehmann-ChePhuong L. MaiDavid MalkinUte M. MollJeffrey N. MyersKim E. NicholsSarka PospisilovaPatricia Ashton-ProllaDavide RossiSharon A. SavageLouise C. StrongPatricia N. ToninRobert ZeillingerThorsten ZenzJoseph F. FraumeniPeter E.M. TaschnerPierre HainautThierry Soussi

medicinevariant interpretationgeneticsgenetic variationallelic variantclinical researchclinical practicesupplementary figures

The Nfia-Eto2 Fusion Blocks Erythroid Maturation and Induces Pure Erythroid Leukemia in Cooperation With Mutant Tp53. Blood (2023)

Maria-Riera Piqué-BorràsZivojin JevticFrederik Otzen BaggerJonathan SeguinRathick SivalingamMatheus Filgueira BezerraAmber LouwaigeSabine JugeIoannis NellasRobert IvanekAlexandar TzankovUte MollOriano Valerio CantilloRamona Schulz-HeddergottAlexandre FagnanThomas MercherJuerg Schwaller

hematological malignanciescarcinogenesisdermatologygene expressionpharmacologycancer geneticshematologymolecular cancergeneticscancer genomicsoncogenesmedicinal researchcancer biologytumor biology

1
2
3
4
5
18
10 / page

Ute Moll

Professor

Stony Brook University

Affiliations

Renaissance School of Medicine

Pathology

Ute Moll is currently serving as a Pathology Professor at Stony Brook University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Ute Moll

Stony Brook University

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

CORRECTION: Dynamics of Clonal Hematopoiesis Under Dna-Damaging Treatment in Patients With Ovarian Cancer. Leukemia (2024)

Correction to: Two Hot Spot Mutant P53 Mouse Models Display Differential Gain of Function in Tumorigenesis. Cell Death and Differentiation (2024)

W HanelN MarchenkoS XuS Xiaofeng YuW WengU Moll

cellular senescencecell deathcancer geneticsdifferential gaingeneticsbiologyoncogenescancer cellstumor microenvironmentcancer biologycellular differentiationtumor biologycell biology

Enhancement of Colorectal Cancer Therapy Through Interruption of the Hsf1-Hsp90 Axis by P53 Activation or Cell Cycle Inhibition. bioRxiv (Cold Spring Harbor Laboratory) (2024)

pharmacologycell cycle inhibitiononcologycolorectal cancercolorectal cancer therapy

Gene Expression Markers in Peripheral Blood and Outcome in Patients With Platinum‐Resistant Ovarian Cancer: A Study of the European Gannet53 Consortium. International Journal of Cancer (2024)

Clonal Hematopoiesis in Whole-Blood and Cell-Free Dna of Ovarian Cancer Patients Undergoing Parp-Inhibitor Treatment: An Exploratory Analysis of the Engot-Ov48/Eudario Trial. Blood (2023)

Data From Mitochondrially Targeted P53 Has Tumor Suppressor Activities I in Vivo /I. (2023)

Flaminia TalosOleksi PetrenkoPatricio MenaUte M. Moll

cancer geneticscancer researchmolecular cancermitochondrial functiongeneticstumor suppressorsmolecular biologyoncologyneuro-oncologycancer biologytumor biology

Epichaperome Inhibition Targets Tp53- Mutant Aml and Aml Stem/Progenitor Cells. Blood (2023)

medicinegene expressioncancer geneticshematologycancer researchgeneticsmolecular biologytumor biology

Supplementary Figure Legends From Mitochondrially Targeted P53 Has Tumor Suppressor Activities I in Vivo /I. (2023)

Flaminia TalosOleksi PetrenkoPatricio MenaUte M. Moll

Supplementary Figures From Recommended Guidelines for Validation, Quality Control, and Reporting of Tp53 Variants in Clinical Practice. (2023)

medicinevariant interpretationgeneticsgenetic variationallelic variantclinical researchclinical practicesupplementary figures

The Nfia-Eto2 Fusion Blocks Erythroid Maturation and Induces Pure Erythroid Leukemia in Cooperation With Mutant Tp53. Blood (2023)

hematological malignanciescarcinogenesisdermatologygene expressionpharmacologycancer geneticshematologymolecular cancergeneticscancer genomicsoncogenesmedicinal researchcancer biologytumor biology

1
2
3
4
5
18
10 / page

Similar Faculty Members

Devanand Sarkar

Institution

Virginia Commonwealth University

oncology

cancer research

Wael El-Rifai

Institution

University of Miami

molecular cancer

cancer biology

Aristotelis Tsirigos

Institution

New York University

hi-c data analysis

health informatics

Jonathan D Licht

Institution

University of Florida

oncology

pathology

Harold L. Moses

Institution

Vanderbilt University

oncogene

molecular cancer

Charles Eberhart

Institution

Johns Hopkins University

oncology

neurology

Michele Pagano, MD

Institution

New York University

cell cycle

cell cycle control

Justin D. Lathia

Institution

Case Western Reserve University

oncology

brain tumor research

Amato J. Giaccia

Institution

Stanford University

radiation oncology

cancer biology

Stephen D. Nimer

Institution

University of Miami

molecular biology

haematopoiesis

Similar Faculty Members

Devanand Sarkar

Institution

Virginia Commonwealth University

oncology

cancer research

Wael El-Rifai

Institution

University of Miami

molecular cancer

cancer biology

Aristotelis Tsirigos

Institution

New York University

hi-c data analysis

health informatics

Jonathan D Licht

Institution

University of Florida

oncology

pathology

Harold L. Moses

Institution

Vanderbilt University

oncogene

molecular cancer

Charles Eberhart

Institution

Johns Hopkins University

oncology

neurology

Michele Pagano, MD

Institution

New York University

cell cycle

cell cycle control

Justin D. Lathia

Institution

Case Western Reserve University

oncology

brain tumor research

Amato J. Giaccia

Institution

Stanford University

radiation oncology

cancer biology

Stephen D. Nimer

Institution

University of Miami

molecular biology

haematopoiesis